Platelet activation relieves liver portal hypertension via the lymphatic system though the classical vascular endothelial growth factor receptor 3 signaling pathway

Figure 6 Inhibition of vascular endothelial growth factor C/vascular endothelial growth factor receptor 3 reversed the amelioration of liver fibrosis and portal hypertension in platelet-rich plasma-induced platelets. A: Representative immunohistochemistry images of hematoxylin and eosin (H&E), Masson’s trichrome, and Sirius red staining in liver samples from the different groups; Quantitative analysis of B: Masson’s trichrome; C: Sirius Red; D: Protein expression of alpha smooth muscle actin (α-SMA) in the different groups; Quantitative analysis of E: α-SMA staining; F: The levels of portal pressure were also measured. The data represent the mean ± SD. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. BDL: Bile duct ligation; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PP: Portal pressure; PRP: Platelet-rich plasma; VEH: Vehicle.